MEDS VS RUBY Stock Comparison

Performance

MEDS
10/100

MEDS returned -41.09% in the last 12 months. Based on SPY's performance of -13.95%, its performance is below average giving it a score of 10 of 100.

RUBY
10/100

RUBY returned -98.07% in the last 12 months. Based on the other stocks in it's sector with an average return of -23.41%, it's performance is below average giving it a grade of 10 of 100.

Technicals

MEDS
36/100

MEDS receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

RUBY
11/100

RUBY receieves a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

MEDS
10/100

MEDS has missed earnings 9 times in the last 20 quarters.

RUBY
10/100

RUBY has missed earnings 10 times in the last 20 quarters.

Profit

MEDS
22/100

Out of the last 20 quarters, MEDS has had 6 profitable quarters and has increased their profits year over year on 2 of them.

RUBY
10/100

Out of the last 16 quarters, RUBY has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

MEDS
52/100

MEDS has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

RUBY
60/100

RUBY has had a higher than average amount of volatility over the last 12 months giving it a grade of 60 of 100.

Sentiment

MEDS

"Sentiment" not found for MEDS

RUBY
74/100

RUBY had a bullish sentiment score of 73.52% across Twitter and StockTwits over the last 12 months. It had an average of 112.63 posts, 390,651.67 comments, and 275,565.84 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

TRxADE HEALTH, Inc. Common Stock Summary

Nasdaq / MEDS

Healthcare

Medical - Pharmaceuticals

TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.

Rubius Therapeutics, Inc Summary

Nasdaq / RUBY

Healthcare

Biotechnology

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Power up your portfolio